PharmaSGP IPO Initiation: Potent Medicine
PharmaSGP (1780644D GR) is a pure-play consumer health company with a broad portfolio of leading chemical-free non-prescription pharmaceuticals...
362 Views
Medigene - Termination of coverage
Edison Investment Research is terminating coverage on Medigene, PetroMatad, Brady and Stride Gaming. Please note you should no longer rely on any...
477 Views
Medigene - Q319 results highlight successful year to date
Enrolment of patients in Medigene’s MDG1011 Phase I/II trial continues, albeit at a slower rate than initially expected, with initial data from the...
772 Views
Medigene - Financial strength through trial readouts
In H118, Medigene announced several key developments including the start of its MDG1011 Phase I/II TCR clinical trial, a gross capital raise of...
51 Views
Medigene - bluebird bio back for more
Medigene has announced an expansion of its bluebird partnership, giving significant external validation of its T-cell receptor (TCR) technology...
69 Views
No more insights